Ask the Expert

Our ‘Ask the Expert’ initiative offers you the chance to enter into discussion with a leading expert on your topic of interest related to ECP and its clinical applications.

All appointments offered through this initiative are private, one-to-one sessions in which you can connect with your chosen expert through a secure weblink. The service is fully funded by the Therakos Institute.

Request to book a session

To book an appointment, please make sure you are logged in

Filter by:

Prof Hildegard Greinix

Institution:

Medical University of Vienna, Austria

Speciality:

Hematology, Stem Cell Transplantation, Cellular Immunotherapy

Therapeutic Areas of interest:

ECP in GvHD

See full profile

Prof Jan P Nicolay

Institution:

University Hospital Mannheim GmbH, Germany

Speciality:

Department of Dermatology, Venereology and Allergology

Therapeutic Areas of interest:

ECP in CTCL

See full profile

Prof. Dr. med. Markus J. Barten

Institution:

University Heart & Vascular Center Hamburg, Department of Cardiovascular Surgery, Germany

Speciality:

Heart and Lung Transplantation (HTx and LuTx)

Therapeutic Areas of interest:

ECP in Heart Transplantation

See full profile

Dr Anna Colpo

Institution:

Azienda Ospedale Università di Padova, Department of Transfusion Medicine, Italy

Speciality:

Therapeutic Apheresis, Transfusion Medicine

Therapeutic Areas of interest:

ECP in GvHD
ECP in Lung Transplantation

See full profile

Dr James Griffin

Institution:

Bristol Hematology & Oncology Centre, UK

Speciality:

Hematology

Therapeutic Areas of interest:

ECP in GvHD

See full profile

Prof Peter Jaksch

Institution:

Medical University of Vienna, Austria

Speciality:

Solid Organ Transplantation

Therapeutic Areas of interest:

ECP in Lung Transplantation

See full profile

Dr Wolfgang Mayer

Institution:

Tirol Kliniken, Innsbruck, Austria

Speciality:

Transfusion Medicine

Therapeutic Areas of interest:

ECP in all therapeutic areas from the service provider's view

See full profile

Dr Nicola Piccirillo

Institution:

Fondazione Policlinico Universitario A. Gemelli Rome, Italy

Speciality:

ECP Service and Patient Access

Therapeutic Areas of interest:

ECP in GvHD

See full profile

Prof Julia Scarisbrick

Institution:

University Hospital Birmingham, UK

Speciality:

Dermatology

Therapeutic Areas of interest:

ECP in Dermatologic Diseases

See full profile

Prof Daniel Wolff

Institution:

University Hospital Regensburg, Germany

Speciality:

Hematology

Therapeutic Areas of interest:

ECP in chronic GvHD

See full profile

Prof Nina Worel

Institution:

Medical University of Vienna, Austria

Speciality:

Transfusion Medicine

Therapeutic Areas of interest:

ECP in acute and chronic GvHD and in heart and lung transplantation

See full profile

Prof Robert Zeiser

Institution:

University Hospital Freiburg, Germany

Speciality:

Hematology, Immunology

Therapeutic Areas of interest:

ECP in GvHD

See full profile

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Ask the Expert

Our ‘Ask the Expert’ initiative offers you the chance to enter into discussion with a leading expert on your topic of interest related to ECP and its clinical applications.

Request to book a session

Prof Hildegard Greinix

Prof Jan P Nicolay

Prof. Dr. med. Markus J. Barten

Dr Anna Colpo

Dr James Griffin

Prof Peter Jaksch

Dr Wolfgang Mayer

Dr Nicola Piccirillo

Prof Julia Scarisbrick

Prof Daniel Wolff

Prof Nina Worel

Prof Robert Zeiser

Discover more

Courses

Webinars

Symposia

Speaker Meetings

Welcome to the Home of ECP

Thank you for visiting therakos.eu.

You are leaving the therakos.eu website.

Welcome to the Therakos Institute

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS